ReproCell

ReproCell Gross Margin

The Gross Margin of ReproCell (4978.T) as of Oct 20, 2026 is 45.34 %. In the previous year, Gross Margin was 54.74 % — a change of -17.18% (lower).

Gross Margin

45.34 %

YoY

-17.18%

Last updated:

Gross Margin of ReproCell is 2026 45.34 % . Gross Margin of ReproCell was 2025 54.74 % . It decreases by -17.18% lower compared to the previous year.

For ReproCell, the gross margin of 45.3% is up versus 35.1% a few years ago.

The ReproCell Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
42.43 JPY
Jan 1, 2020
36.11 JPY
Jan 1, 2021
35.46 JPY
Jan 1, 2022
35.15 JPY
Jan 1, 2023
38.18 JPY
Jan 1, 2024
45.52 JPY
Jan 1, 2025
54.74 JPY
Jan 1, 2026
45.34 JPY
The ReproCell Gross Margin history
YEARGross MarginYoY
45.34 %-17.18%
54.74 %+20.26%
45.52 %+19.21%
38.18 %+8.64%
35.15 %-0.87%
35.46 %-1.80%
36.11 %-14.90%
42.43 %+167.93%
15.84 %-41.84%
27.23 %+19.61%
22.77 %-53.24%
48.69 %-12.37%
55.56 %+10,638.13%
0.52 %+9.30%
0.47 %+6.54%
0.44 %-8.63%
0.49 %-6.46%
0.52 %-3.48%
0.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Gross Margin of ReproCell is 45.34 % in 2026.

Gross Margin of ReproCell changed from 54.74 % to 45.34 %, representing a -17.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin ReproCell since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's ReproCell with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — ReproCell

All Key Metrics — ReproCell